Medicare AdvantageCoverageMedium impact
MA08.171, ADAMTS13, recombinant-krhn (Adzynma)
Independence Blue Cross·Hematology, Oncology·Medical Policy
Effective date
May 28, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.171 for ADAMTS13, recombinant-krhn (Adzynma) has been reissued and will take effect on May 28, 2025. This policy addresses coverage and billing requirements for this specialized hemophilia treatment medication.
Action Required
Before May 28, 2025: Billing team should review the complete policy details at the source URL to understand specific coverage criteria and billing requirements for ADAMTS13, recombinant-krhn (Adzynma). Update billing protocols and prior authorization processes as specified in the full policy once details are available.